Vepdegestrant in Phase 3: How Strong Are Its Chances?
What Is Vepdegestrant? Vepdegestrant (ARV-471) is a PROTAC® (Proteolysis Targeting Chimera)-based oral SERD designed to degrade estrogen receptor alpha (ERα),...
PROTAC / Heterobifunctional
The BTK Degrader Revolution: How BeiGene’s BGB-16673 Could Redefine Blood Cancer Treatment with Phase III Breakthrough
Bruton’s tyrosine kinase (BTK) has been a cornerstone target in B‑cell malignancies for over a decade, but resistance to BTK...